253 related articles for article (PubMed ID: 15615495)
1. RANK, RANKL and OPG in inflammatory arthritis and periprosthetic osteolysis.
Ritchlin CT; Schwarz EM; O'Keefe RJ; Looney RJ
J Musculoskelet Neuronal Interact; 2004 Sep; 4(3):276-84. PubMed ID: 15615495
[TBL] [Abstract][Full Text] [Related]
2. Interface tissue fibroblasts from loose total hip replacement prosthesis produce receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and cathepsin K.
Mandelin J; Li TF; Hukkanen M; Liljeström M; Salo J; Santavirta S; Konttinen YT
J Rheumatol; 2005 Apr; 32(4):713-20. PubMed ID: 15801030
[TBL] [Abstract][Full Text] [Related]
3. Expression of inflammatory cytokines, RANKL and OPG induced by titanium, cobalt-chromium and polyethylene particles.
Masui T; Sakano S; Hasegawa Y; Warashina H; Ishiguro N
Biomaterials; 2005 May; 26(14):1695-702. PubMed ID: 15576143
[TBL] [Abstract][Full Text] [Related]
4. Anti-RANKL therapy for inflammatory bone disorders: Mechanisms and potential clinical applications.
Anandarajah AP; Schwarz EM
J Cell Biochem; 2006 Feb; 97(2):226-32. PubMed ID: 16240334
[TBL] [Abstract][Full Text] [Related]
5. Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease.
Sattler AM; Schoppet M; Schaefer JR; Hofbauer LC
Calcif Tissue Int; 2004 Jan; 74(1):103-6. PubMed ID: 14523602
[TBL] [Abstract][Full Text] [Related]
6. Receptor activator of nuclear factor kappaB ligand is expressed in resident and inflammatory cells in aseptic and septic prosthesis loosening.
Gehrke T; Sers C; Morawietz L; Fernahl G; Neidel J; Frommelt L; Krenn V
Scand J Rheumatol; 2003; 32(5):287-94. PubMed ID: 14690142
[TBL] [Abstract][Full Text] [Related]
7. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling.
Theoleyre S; Wittrant Y; Tat SK; Fortun Y; Redini F; Heymann D
Cytokine Growth Factor Rev; 2004 Dec; 15(6):457-75. PubMed ID: 15561602
[TBL] [Abstract][Full Text] [Related]
8. The OPG/RANKL/RANK system in metabolic bone diseases.
Hofbauer LC; Kühne CA; Viereck V
J Musculoskelet Neuronal Interact; 2004 Sep; 4(3):268-75. PubMed ID: 15615494
[TBL] [Abstract][Full Text] [Related]
9. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK.
Théoleyre S; Kwan Tat S; Vusio P; Blanchard F; Gallagher J; Ricard-Blum S; Fortun Y; Padrines M; Rédini F; Heymann D
Biochem Biophys Res Commun; 2006 Aug; 347(2):460-7. PubMed ID: 16828054
[TBL] [Abstract][Full Text] [Related]
10. Heritable disorders of the RANKL/OPG/RANK signaling pathway.
Whyte MP; Mumm S
J Musculoskelet Neuronal Interact; 2004 Sep; 4(3):254-67. PubMed ID: 15615493
[TBL] [Abstract][Full Text] [Related]
11. RANKL-RANK signaling in osteoclastogenesis and bone disease.
Wada T; Nakashima T; Hiroshi N; Penninger JM
Trends Mol Med; 2006 Jan; 12(1):17-25. PubMed ID: 16356770
[TBL] [Abstract][Full Text] [Related]
12. Identification of the osteoprotegerin/receptor activator of nuclear factor-kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis.
Lu HK; Chen YL; Chang HC; Li CL; Kuo MY
J Periodontal Res; 2006 Aug; 41(4):354-60. PubMed ID: 16827732
[TBL] [Abstract][Full Text] [Related]
13. RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis.
Pettit AR; Walsh NC; Manning C; Goldring SR; Gravallese EM
Rheumatology (Oxford); 2006 Sep; 45(9):1068-76. PubMed ID: 16490750
[TBL] [Abstract][Full Text] [Related]
14. Arthroplasty membrane-derived fibroblasts directly induce osteoclast formation and osteolysis in aseptic loosening.
Sabokbar A; Itonaga I; Sun SG; Kudo O; Athanasou NA
J Orthop Res; 2005 May; 23(3):511-9. PubMed ID: 15885469
[TBL] [Abstract][Full Text] [Related]
15. Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand system in the early post-operative period of liver transplantation.
Fábrega E; Orive A; García-Unzueta M; Amado JA; Casafont F; Pons-Romero F
Clin Transplant; 2006; 20(3):383-8. PubMed ID: 16824158
[TBL] [Abstract][Full Text] [Related]
16. [Clinical implications of new insights into the regulation of bone resorption].
Lems WF; Bijlsma JW
Ned Tijdschr Geneeskd; 2005 Jul; 149(30):1664-7. PubMed ID: 16104110
[TBL] [Abstract][Full Text] [Related]
17. Effects of polyethylene and TiAlV wear particles on expression of RANK, RANKL and OPG mRNA.
Baumann B; Rader CP; Seufert J; Nöth U; Rolf O; Eulert J; Jakob F
Acta Orthop Scand; 2004 Jun; 75(3):295-302. PubMed ID: 15260421
[TBL] [Abstract][Full Text] [Related]
18. Alpha-lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio in human bone marrow stromal cells.
Koh JM; Lee YS; Byun CH; Chang EJ; Kim H; Kim YH; Kim HH; Kim GS
J Endocrinol; 2005 Jun; 185(3):401-13. PubMed ID: 15930166
[TBL] [Abstract][Full Text] [Related]
19. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio.
Kiviranta R; Morko J; Alatalo SL; NicAmhlaoibh R; Risteli J; Laitala-Leinonen T; Vuorio E
Bone; 2005 Jan; 36(1):159-72. PubMed ID: 15664014
[TBL] [Abstract][Full Text] [Related]
20. Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization.
Sandberg WJ; Yndestad A; Øie E; Smith C; Ueland T; Ovchinnikova O; Robertson AK; Müller F; Semb AG; Scholz H; Andreassen AK; Gullestad L; Damås JK; Frøland SS; Hansson GK; Halvorsen B; Aukrust P
Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):857-63. PubMed ID: 16424351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]